Company profile · Software
BIO KEY International Inc (BKYI)
Nasdaq: BKYI · Holmdel, NJ · Data from SEC filings, updated Oct 6, 2026
Overview
BIO KEY International Inc trades on Nasdaq under the ticker BKYI and is classified by RoxMag in the Software segment (SEC industry code 7372, Services-Prepackaged Software). Its principal executive offices are in Holmdel, NJ. In its annual report for the fiscal year ended December 31, 2025, it reported revenue of $5.9 million and a net loss of $7.2 million. By public float it ranks #148 of the 153 software companies profiled on RoxMag.
Financial history
Annual figures as reported in BIO KEY INTERNATIONAL INC's 10-K filings (US dollars).
- Revenue growth
- -14.3%
- vs prior year, FY2025
- Net margin
- -120.6%
- net income ÷ revenue, FY2025
- Operating margin
- -115.0%
- operating income ÷ revenue, FY2025
- R&D share of revenue
- 44.0%
- R&D ÷ revenue, FY2025
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $5.9M | $6.9M | $7.8M | $7.0M | $5.1M |
| Gross profit | $4.6M | $5.6M | $1.4M | $4.6M | $3.4M |
| Operating income | -$6.8M | -$4.0M | -$8.8M | -$9.9M | -$4.9M |
| Net income | -$7.2M | -$4.3M | -$8.5M | -$11.9M | -$5.1M |
| Research & development | $2.6M | $2.5M | $2.4M | $3.3M | $2.4M |
| Total assets | $8.3M | $8.6M | $4.5M | $11.3M | $17.8M |
| Stockholders' equity | $5.1M | $3.8M | $1.1M | $5.3M | $15.6M |
| Cash & equivalents | $2.7M | $437,604 | $511,400 | $2.6M | $7.8M |
Fiscal-year labels follow the calendar year in which each fiscal year ends. Margins and growth are calculated by RoxMag from the reported figures.
Recent SEC filings
Sources & method
Company identity, address, filings, financial figures, share counts and public float come from the company's own filings with the U.S. Securities and Exchange Commission (EDGAR). Website, founding year, chief executive and employee count come from Wikidata where available; the overview excerpt is from Wikipedia. Fields without a public source are left blank. RoxMag does not estimate figures. This page is general information, not investment advice — see our disclaimer and editorial policy.